Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service, Personnel

Dr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster

The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D. successfully completed a percutaneous femoral-popliteal artery bypass at the Leominster, Mass. location of TVCG, marking one of the first such procedures in an outpatient setting in the state. TVCG has centered its treatment model around optimizing the patient experience, providing advanced vascular interventions outside of the traditional hospital setting, and mitigating unnecessary expense. The success of this cutting-edge, minimally invasive procedure marks another step toward that mission.

The procedure was part of an investigational device exemption (IDE) trial called DETOUR2 Continued Access (NCT04625660), sponsored by Endologix LLC. The trial is evaluating the safety and effectiveness of the PQ Bypass System for a percutaneous femoral-popliteal bypass procedure. The PQ Bypass System was designated as a U.S. Food and Drug Administration (FDA) Breakthrough Device in 2020.

"By offering this type of minimally invasive procedure in the outpatient setting, we can help patients avoid a surgical incision, hospitalization and postoperative recovery," said Dr. Hoenig. "The patient was discharged two hours after the procedure with no discomfort and only two small, quarter-inch access incisions. This clearly changes our approach to limb threatening disease. I feel privileged to be one of the first vascular surgeons in Massachusetts to perform the procedure."

Dr. Hoenig performed the procedure in his Leominster vascular center. The patient was placed under light conscious sedation and was sent home to recover a few hours later. This advancement in treatment was performed in concert with Vascular Breakthroughs, a clinical trials management platform.

"This is an impressive achievement for both Dr. Hoenig and The Vascular Care Group," said Dr. Paul Gagne, founder of Vascular Breakthroughs, the clinical trials research organization supporting Dr. Hoenig. "The procedure expands the possibilities of vascular care in the outpatient setting and provides patients with better outcomes in a patient-friendly environment."

The percutaneous bypass graft is used to restore blood flow to the lower leg and foot using a minimally invasive technique that avoids hospitalization and long recovery. With this new procedure, The Vascular Care Group is providing new technologies and techniques to community physicians working outside of large research centers, enabling greater access to medical innovation in a safe, efficient, patient-friendly setting. It marks another step in granting communities access to cutting-edge technology on a local level at a lower cost, without requiring a trip to a major city, or a long hospital stay.

The PQ Bypass System is limited by federal law to investigational use only and is not available for sale.

About The Vascular Care Group

The Vascular Care Group (TVCG) is a growing group practice committed to the prevention, diagnosis, and treatment of vascular disease. The practice brings together decades of expertise among a team of vascular specialists offering unparalleled care in Massachusetts at four full-service vascular care centers with five satellite offices, from Worcester to Cape Cod. Their comprehensive services cover a broad range of conditions from non-invasive vascular testing to complex vascular surgeries, including a full spectrum of open and endovascular procedures performed in-office and at affiliated hospitals throughout the state. The care center has united some of the area's leading vascular experts with a focus on superior patient care. More information about the practice can be found at https://vascularcaregrp.com/.

About Vascular Breakthroughs

Vascular Breakthroughs was founded by Paul J. Gagne MD, FACS, RVT in 2012 to provide a research infrastructure for physicians not affiliated with an academic institution. The organization has put new technologies in the hands of physicians working in the community, thereby improving access to novel treatments for patients and expanding the reach of cutting-edge research. Vascular Breakthroughs provides administrative support for all aspects of the implementation of a clinical trial, including recruitment, all phases in the initiation of a new trial and in the execution of a trial. More information about Vascular Breakthroughs can be found at https://vascularbreakthroughs.com/.

These press releases may also interest you

at 01:05
BeiGene, Ltd. , a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization,...

at 01:00
Peregrine Connect Application, API, and Workflow integration platform has been selected by D&H Distributing to increase their volume of transactions, integrate with existing applications and platforms, and reduce development & deployment costs. D&H...

at 01:00
BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug...

at 01:00
BEST Inc. ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2022, after...

at 00:30
In a world of 3D printed homes and furniture, the need for lightweight structured materials has never been greater. That's where PrintFoam comes in ? it's a start-up company that specializes in 3D printing resins that make foam parts. PrintFoam's...

at 00:20
Quadric, a leading processor technology intellectual property (IP) licensor, and MegaChips, a leading ASIC and SoC services company based in Japan, today announced a strategic partnership to deliver ASIC and SoC solutions built on Quadric's...

News published on 11 january 2022 at 10:50 and distributed by: